Barinthus Biotherapeutics plc (NASDAQ:BRNS – Get Free Report) saw a large drop in short interest in February. As of February 28th, there was short interest totalling 11,300 shares, a drop of 19.9% from the February 13th total of 14,100 shares. Based on an average trading volume of 38,300 shares, the short-interest ratio is presently 0.3 days. Currently, 0.0% of the company’s stock are sold short.
Barinthus Biotherapeutics Stock Performance
Barinthus Biotherapeutics stock opened at $1.06 on Monday. The firm’s 50-day moving average is $1.02 and its 200-day moving average is $1.13. Barinthus Biotherapeutics has a 1 year low of $0.80 and a 1 year high of $4.16. The company has a market cap of $42.64 million, a P/E ratio of -0.71 and a beta of -0.80.
Analyst Upgrades and Downgrades
Separately, HC Wainwright decreased their price objective on shares of Barinthus Biotherapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a report on Monday, January 13th.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Barinthus Biotherapeutics stock. Gilead Sciences Inc. purchased a new position in Barinthus Biotherapeutics plc (NASDAQ:BRNS – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 620,351 shares of the company’s stock, valued at approximately $749,000. Barinthus Biotherapeutics comprises about 0.0% of Gilead Sciences Inc.’s holdings, making the stock its 14th biggest position. Gilead Sciences Inc. owned approximately 1.54% of Barinthus Biotherapeutics as of its most recent filing with the Securities and Exchange Commission. 25.20% of the stock is currently owned by hedge funds and other institutional investors.
Barinthus Biotherapeutics Company Profile
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.
Read More
- Five stocks we like better than Barinthus Biotherapeutics
- What is the Australian Securities Exchange (ASX)
- How to Build the Ultimate Everything ETF Portfolio
- What Are Earnings Reports?
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- How to Effectively Use the MarketBeat Ratings Screener
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Barinthus Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barinthus Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.